Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)

#2940

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.

Aim(s): To investigate the efficacy of Avelumab, an anti-PD-L1 monoclonal antibody, in poorly differentiated, G3 NECs.

Materials and methods: The NET001 study (NCT03278405) is a single center, phase IIA study of Avelumab, (10mg/kg/IV every 2 weeks for a period of 52 weeks) in pts with poorly differentiated, WHO 2010 G3 NECs, from a gastrointestinal (GI) or lung source, who have progressed on a maximum of 2 lines of prior therapy.. The primary endpoint was ORR by RECIST v1.1; secondary endpoints included mPFS, mOS, DCR at 6 months, and toxicity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rodriguez-Freixinos V

Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,

Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,